- Home
- TLRY vs DSGN Comparison
TLRY vs DSGN Comparison
Compare TLRY & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | DSGN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 819.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLRY | DSGN |
|---|---|---|
| Price | $5.31 | $11.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $72.33 | $15.25 |
| AVG Volume (30 Days) | ★ 5.7M | 1.1M |
| Earning Date | 04-01-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.79 | N/A |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $3.33 |
| 52 Week High | $15.70 | $17.25 |
Technical Indicators
Market Signals| Indicator | TLRY | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.07 | 40.09 |
| Support Level | $1.12 | $9.25 |
| Resistance Level | $7.01 | $13.54 |
| Average True Range (ATR) | 0.21 | 1.32 |
| MACD | -0.00 | -0.52 |
| Stochastic Oscillator | 23.88 | 16.83 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.